Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

517.33
Delayed Data
As of 4:00pm ET
 -9.20 / -1.75%
Today’s Change
325.35
Today|||52-Week Range
543.55
+40.93%
Year-to-Date
Trump's Drug Pricing News Boosts Biotechs
5:25pm / TheStreet.com - Paid Partner Content
Rigel Pharmaceuticals' NDA for Tavalisse Accepted by FDA
Jun 20 / Zacks.com - Paid Partner Content
Regeneron (REGN) Stock on Fire: What's Behind the Surge?
10:40am / Zacks.com - Paid Partner Content
J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study
Jun 20 / Zacks.com - Paid Partner Content
Here's Why Investors Are Glued to Vertex Pharma (VRTX) Stock
10:40am / Zacks.com - Paid Partner Content
Amgen's Xgeva Myeloma Label Expansion sBLA Accepted by FDA
Jun 20 / Zacks.com - Paid Partner Content
Kamada Withdraws Inhaled AAT Marketing Application in EU
10:40am / Zacks.com - Paid Partner Content
Merrimack Completes Enrollment in Phase II Study for MM-141
Jun 20 / Zacks.com - Paid Partner Content
Biotech Movers: Regeneron Slides Back After Big Gains
9:49am / TheStreet.com - Paid Partner Content
CAI International, Kroger, Broadcom, Regeneron and Vodafone Group highlighted as Zack...
Jun 20 / Zacks.com - Paid Partner Content
Here's Why Geron (GERN) is a Good Stock to Invest in Now
Jun 22 / Zacks.com - Paid Partner Content
A Lazy, Unfocused Summer Is Here: Global Week Ahead
Jun 19 / Zacks.com - Paid Partner Content
Indivor's Opioid Use Disorder Drug Meets Primary Endpoint
Jun 22 / Zacks.com - Paid Partner Content
GlaxoSmithKline's Benlysta Positive in Continuation Trial
Jun 19 / Zacks.com - Paid Partner Content
BioDelivery Inks New Contract with CVS/Caremark, Shares Up
Jun 22 / Zacks.com - Paid Partner Content
Pfizer & Lilly Get Fast Track Designation for Pain Candidate
Jun 14 / Zacks.com - Paid Partner Content
AveXis (AVXS) Jumps: Stock Rises 7.1%
Jun 22 / Zacks.com - Paid Partner Content
Zacks.com featured highlights: Regeneron Pharmaceuticals, Raymond James Financial, Do...
Jun 14 / Zacks.com - Paid Partner Content
Strength Seen in Arena Pharmaceuticals (ARNA): Stock Up 5.4%
Jun 22 / Zacks.com - Paid Partner Content
GTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up
Jun 13 / Zacks.com - Paid Partner Content
Cramer: This Is No Country for Old Value
Jun 21 / TheStreet.com - Paid Partner Content
5 Stocks with Solid Sales Growth Catching Eyeballs
Jun 13 / Zacks.com - Paid Partner Content
Pharma recovers composure as price concerns ease
Jun 21 / FT.com - Paid Partner Content
Lilly Plans New Outcomes Study to Expand Jardiance Label
Jun 13 / Zacks.com - Paid Partner Content
Novartis Migraine Drug Accepted, AMD Positive in Phase III
Jun 21 / Zacks.com - Paid Partner Content
J&J Announces EU Regulatory Approval for Actelion Deal
Jun 12 / Zacks.com - Paid Partner Content
Fresh Capital to Be Injected into Biotech Stocks: 5 Must-Buys
Jun 21 / Zacks.com - Paid Partner Content
Sanofi/Regeneron's Praluent Cuts Bad Cholesterol in Studies
Jun 12 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt
Jun 21 / Zacks.com - Paid Partner Content
Regeneron (REGN) Up 7.3% Since Earnings Report: Can It Continue?
Jun 09 / Zacks.com - Paid Partner Content
Vanda Pharmaceuticals (VNDA) Worth a Look: Stock Jumps 8%
Jun 21 / Zacks.com - Paid Partner Content
Pfizer raises US prices of 91 drugs by 20% in 2017
Jun 02 / FT.com - Paid Partner Content